Oracle's AI Ambitions Face a Financing Reckoning as Investors Demand the Revenue Roadmap

Oracle's stock has shed 29% since the start of the year, and the pressure is coming from two directions at once: a capital-intensive data-center buildout that needs to be paid for, and a market that wants to see how those investments turn into revenue. The company's upcoming investor day on October 28 is shaping up as the moment of truth.

TD Cowen analyst Michael Elias floated a possible lifeline on Tuesday, suggesting Nvidia could back Oracle's financing in various ways—guaranteeing lease payments, or leasing data-center space itself and subletting it to Oracle. Neither company has confirmed any such arrangement, and the scope and terms remain unknown. Oracle is also reportedly exploring supplier financing, according to the report.

The sums involved are substantial. Oracle invested $28.5 billion in the quarter, up from $8.5 billion in the year-earlier period, according to media reports. Adjusted free cash flow came in at negative $5.4 billion. As of August 31, the company carried additional lease obligations of $288 billion, predominantly for data centers. For fiscal 2027, Oracle planned to raise roughly $40 billion through debt and equity.

A guarantee could shore up financing, but it would not prove that the additional capacity is already profitable—a distinction that matters for valuation. Access to capital and economic return are two separate questions.

AstraZeneca Deal Shows the Art of the Possible

Oracle offered a concrete illustration of where its technology could be applied with the planned AI collaboration with AstraZeneca, announced Tuesday. The companies aim to identify suitable trial participants earlier, make clinical studies more efficient, and better translate research findings into care. Additional applications could include earlier diagnoses and monitoring of drug safety.

The first program is slated to focus on hypertension care and clinical research in Abu Dhabi with M42. Further projects are planned in the U.S., the Middle East, and Europe, using de-identified data. AstraZeneca will not receive identifiable patient data.

The agreement is non-binding, and financial terms were not disclosed. Each project requires its own legal, regulatory, ethical, and institutional reviews, and shared rules for collaboration and measurable success criteria are meant to precede any broader rollout. The cooperation is evidence of potential demand—not of secured revenue.

The Investor Day as a Test

Bank of America's Tal Liani sees the investor day as a possible positive catalyst, with greater clarity on long-term revenue, AI infrastructure, data centers, and financing likely to ease concerns. He confirmed his buy rating on Tuesday with a 12-month price target of $240, raised in June and based on 26.5 times expected calendar-2027 earnings.

JPMorgan analyst Samik Chatterjee is also focused on the event, particularly confirmation of the $225 billion revenue target through fiscal 2029/30 and the interim milestones. He considers a raise to the long-term goals possible—an analyst expectation, not a new company forecast.

The crux is the gap between heavy upfront spending and delayed revenue. Oracle expects fiscal 2027 investments to roughly match expected annual revenue, making financing part of the growth story rather than a footnote. What would be more convincing than the largest possible growth figure is a coherent link between investment, available capacity, revenue development, and funding.

Project Jupiter and the Execution Risk

The project side carries its own hazards. At Project Jupiter in New Mexico, Oracle invoked force majeure to protect itself against cost claims in the event of delays—a step highlighted in a Motley Fool podcast published Tuesday, though the recording dates from September and the commentators stress the reasons are unclear. The planned data center is scheduled to go into operation in 2028. A Blue Owl subsidiary is developing the project, with OpenAI and SoftBank supporting it; Oracle is not exiting, according to a further report.

The permitting dispute drags on. Bloomberg Government reported Tuesday that environmental groups New Energy Economy and the Center for Biological Diversity view their lawsuits as a template for resistance to further U.S. data centers, citing court successes over environmental permitting shortfalls.

For investors, two developments remain decisive: Oracle must convert its strong cloud business—particularly its fast-growing cloud infrastructure segment—into earnings while financing the buildout. Confirmed support from Nvidia could ease the second part. So far, it is only a possibility discussed by TD Cowen, not a committed financing.